MAPK3 and breast cancer: The dysregulated activation of ERK1/2 expression results in malignant transformation, and a high level of phosphorylated ERK1/2 (pERK1/2, activated ERK1/2) has been found to be cellular survival signaling in a variety of human cancerous tissues such as melanoma and breast cancers [41,42].